Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non-Small-Cell Lung Cancer

被引：105

作者：

Chin, Leow Pay ^{[2
]}

Soo, Ross A. ^{[1
,2
]}

Soong, Richie ^{[2
]}

Ou, Sai-Hong I.

机构：

[1] Natl Univ Hlth Syst, Dept Haematol Oncol, Natl Univ Canc Inst, Singapore 119228, Singapore

[2] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore

来源：

JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 11期

关键词：

Non-small-cell lung cancer; Targeted therapy; ROS1; Anaplastic lymphoma kinase inhibitors; Crizotinib; CELL LUNG-CANCER; IN-SITU-HYBRIDIZATION; SOMATIC MUTATIONS; GENE; EXPRESSION; FUSION; TRANSCRIPTOME; ONCOGENE; PATHWAY; ADENOCARCINOMA;

D O I：

10.1097/JTO.0b013e31826baf83

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase have been described in a variety of human malignancies including non-small-cell lung cancer (NSCLC), cholangiocarcinoma and glioblastoma multiforme. Recently, clinicopathologic characteristics of c-ros oncogene 1, receptor tyrosine kinase (ROS1)-rearranged NSCLC patients have been described. Furthermore, anaplastic lymphoma kinase inhibitor, novel class of drugs targeting this tyrosine kinase receptor is currently under clinical trial in this molecular subset of NSCLC patients. This review will focus on the current knowledge of ROS1 rearrangements in NSCLC, methods to detect ROS1 rearrangement, and targeting ROS1-rearranged NSCLC patients with anaplastic lymphoma kinase inhibitors.

引用

页码：1625 / 1630

页数：6

共 40 条

[1]

The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer [J].

Acquaviva, Jaime ;

Wong, Ricky ;

Charest, Al .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2009, 1795 (01) :37-52

[2]

Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[3]

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers [J].

Bergethon, Kristin ;

Shaw, Alice T. ;

Ou, Sai-Hong Ignatius ;

Katayama, Ryohei ;

Lovly, Christine M. ;

McDonald, Nerina T. ;

Massion, Pierre P. ;

Siwak-Tapp, Christina ;

Gonzalez, Adriana ;

Fang, Rong ;

Mark, Eugene J. ;

Batten, Julie M. ;

Chen, Haiquan ;

Wilner, Keith D. ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Carbone, David P. ;

Ji, Hongbin ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari ;

Pao, William ;

Iafrate, A. John .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) :863-870

[4]

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses [J].

Bhattacharjee, A ;

Richards, WG ;

Staunton, J ;

Li, C ;

Monti, S ;

Vasa, P ;

Ladd, C ;

Beheshti, J ;

Bueno, R ;

Gillette, M ;

Loda, M ;

Weber, G ;

Mark, EJ ;

Lander, ES ;

Wong, W ;

Johnson, BE ;

Golub, TR ;

Sugarbaker, DJ ;

Meyerson, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) :13790-13795

[5]

Oncogenic pathway signatures in human cancers as a guide to targeted therapies [J].

Bild, AH ;

Yao, G ;

Chang, JT ;

Wang, QL ;

Potti, A ;

Chasse, D ;

Joshi, MB ;

Harpole, D ;

Lancaster, JM ;

Berchuck, A ;

Olson, JA ;

Marks, JR ;

Dressman, HK ;

West, M ;

Nevins, JR .

NATURE, 2006, 439 (7074) :353-357

[6]

Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21) [J].

Charest, A ;

Lane, K ;

McMahon, K ;

Park, J ;

Preisinger, E ;

Conroy, H ;

Housman, D .

GENES CHROMOSOMES & CANCER, 2003, 37 (01) :58-71

[7]

ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice [J].

Charest, Al ;

Wilker, Erik W. ;

McLaughlin, Margaret E. ;

Lane, Keara ;

Gowda, Ram ;

Coven, Shanie ;

McMahon, Kevin ;

Kovach, Steven ;

Feng, Yun ;

Yaffe, Michael B. ;

Jacks, Tyler ;

Housman, David .

CANCER RESEARCH, 2006, 66 (15) :7473-7481

[8]

Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target [J].

Chiarle, R ;

Simmons, WJ ;

Cai, HY ;

Dhall, G ;

Zamo', A ;

Raz, R ;

Karras, JG ;

Levy, DE ;

Inghirami, G .

NATURE MEDICINE, 2005, 11 (06) :623-629

[9]

The anaplastic lymphoma kinase in the pathogenesis of cancer [J].

Chiarle, Roberto ;

Voena, Claudia ;

Ambrogio, Chiara ;

Piva, Roberto ;

Inghirami, Giorgio .

NATURE REVIEWS CANCER, 2008, 8 (01) :11-23

[10]

Somatic mutations of the protein kinase gene family in human lung cancer [J].

Davies, H ;

Hunter, C ;

Smith, R ;

Stephens, P ;

Greenman, C ;

Bignell, G ;

Teague, B ;

Butler, A ;

Edkins, S ;

Stevens, C ;

Parker, A ;

O'Meara, S ;

Avis, T ;

Barthorpe, S ;

Brackenbury, L ;

Buck, G ;

Clements, B ;

Cole, J ;

Dicks, E ;

Edwards, K ;

Forbes, S ;

Gorton, M ;

Gray, K ;

Halliday, K ;

Harrison, R ;

Hills, K ;

Hinton, J ;

Jones, D ;

Kosmidou, V ;

Laman, R ;

Lugg, R ;

Menzies, A ;

Perry, J ;

Petty, R ;

Raine, K ;

Shepherd, R ;

Small, A ;

Solomon, H ;

Stephens, Y ;

Tofts, C ;

Varian, J ;

Webb, A ;

West, S ;

Widaa, S ;

Yates, A ;

Brasseur, F ;

Cooper, CS ;

Flanagan, AM ;

Green, A ;

Knowles, M .

CANCER RESEARCH, 2005, 65 (17) :7591-7595

← 1 2 3 4 →